Mérieux Equity Partners SAS made an investment in French pharmaceutical laboratory Addmedica SAS through its Mérieux Participations 3 SLP fund.

The private equity firm became the reference shareholder of the company in partnership with founders François Anger and Bernard Dauvergne.

Addmedica develops and markets medicinal products and medical devices for rare diseases, including a benchmark treatment for inherited blood disorder sickle cell disease. The company will use the capital to expand its global footprint and product portfolio.

Duteil et Associés Law Firm and Advance Capital provided support to Mérieux Equity.